Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IL5-R52H4 | Rabbit | Rabbit IL-5 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
IL5-H82Q5 | Human | Biotinylated Human IL-5 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
IL5-H52H3 | Human | Human IL-5 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Loaded Human IL-5, His Tag (Cat. No. IL5-H52H3) on NTA Biosensor, can bind Human IL-5 R alpha, Fc Tag (Cat. No. ILA-H5259) with an affinity constant of 4.63 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Reslizumab | TRFK-5; CDP-835; SCH-5570; CEP-38072; CTx-55700; SCH-55700 | Approved | Teva Pharmaceutical Industries Ltd | Cinqair, Cinquil, Cinqaero | EU | Asthma | s:7:"Teva Bv"; | 2016-03-23 | Pulmonary Eosinophilia; Eosinophilic Esophagitis; Asthma | Details |
Mepolizumab | SB-240563; 240563 | Approved | Glaxosmithkline Plc | Nucala, Bosatria | United States | Hypereosinophilic Syndrome | s:19:"Glaxosmithkline Plc"; | 2015-11-04 | Hypereosinophilic Syndrome; Granulomatosis with Polyangiitis; Churg-Strauss Syndrome; Nasal Polyps; Eosinophilic Esophagitis; Asthma; Eosinophilic Granuloma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
long-acting anti-IL-5 mAb (GSK) | Phase 1 Clinical | Glaxosmithkline Plc | Asthma | Details | |
GSK3511294 | Phase 3 Clinical | Glaxosmithkline Plc | Asthma | Details | |
LP-0058 | LP-0058; LEO-32731 | Phase 2 Clinical | Leo Pharma Inc | Drug-Related Side Effects and Adverse Reactions; Psoriasis; Dermatitis, Atopic | Details |
SHR-1703 | SHR-1703 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Asthma | Details |
Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) | 610 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Autoimmune Diseases; Asthma | Details |
This web search service is supported by Google Inc.